| Document |
Document Title |
|
WO/2006/134487A1 |
The present invention provides for compounds of formula (I) as defined herein. These compounds are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. The compounds are useful for the tr...
|
|
WO/2006/135692A2 |
The present invention provides processes for the production of docetaxel. Docetaxel is produced by protecting the C(7) and the C(10) hydroxy groups of 10-DAB with a bridging silicon-based protecting group. The resulting 7,10 protected 10...
|
|
WO/2006/108561A1 |
A process for the preparation of 10-deacetyl-7,10-bis- trichloroacetylbaccatine III with HPLC purity higher than 99% and free from 2-debenzoyl-2-pentenoylbaccatine III by purification of 10-deacetyl-7,10-bis- trichloroacetylbaccatineIII ...
|
|
WO/2006/102758A1 |
The present invention relates to a new process for the preparation of 9-dihydrobaccatin III intermediates as useful precursors for the preparation of paclitaxel, 1, docetaxel, 2, and analogues thereof. More particularly, the process comp...
|
|
WO/2006/104167A1 |
This invention provides a novel cationically polymerizable oxetane ring-containing 1,3-propanediol derivative and a process for producing the same. A composition comprising a novel oxetane ring-containing 1,3-propanediol derivative, and ...
|
|
WO/2006/102200A2 |
Novel conjugates of docetaxel and novel docetaxel immunogens derived from the 7 and 10 positions of docetaxel and monoclonal antibodies generated by these docetaxel linked immunogens are useful in immunoassays for the quantification and ...
|
|
WO/2006/097262A1 |
The invention discloses novel secotaxane derivatives of general formula 1, having cytotoxic activity, which can be administered through the injective or oral route, for the therapy of tumors.
|
|
WO/2006/093680A1 |
A sprayable energy-curable coating composition comprises an epoxide monomer or oligomer, a cationic photoinitiator and a cyclic carbonate, the cyclic carbonate being present in an amount of at least 7% by weight of the entire composition.
|
|
WO/2006/093548A1 |
The present invention is concerned with certain derivatives of Formula:(I), wherein R, R1 to R10 are as described in the specification, and at least one of CR5R6, or CR7R8, or CR9R10 is a an optionally substituted azetidine ring or an op...
|
|
WO/2006/090057A1 |
The invention concerns a method for preparing paclitaxel characterized in that it consists in starting with 10-deacetylbaccatine in accordance with a 'one-pot' reaction including the following three steps: a) protecting the hydroxy radic...
|
|
WO/2006/090056A1 |
The invention concerns a method for preparing docetaxel from paclitaxel, including the following steps: a) deacylating paclitaxel, b) protecting the free hydroxy functions, in 7-, 10- and 2'-position respectively, c) debenzoylating the a...
|
|
WO/2006/073457A2 |
In one aspect, the present invention provides compounds having formula I or IV as shown below: as further defined herein. In additional aspects, the present invention provides compositions and kits comprising the compounds of the inventi...
|
|
WO/2006/061259A2 |
The present invention relates to novel cytotoxic agents and their therapeutic use. More specifically, the invention relates to novel cytotoxic agents comprising taxanes and their therapeutic use. These novel cytotoxic agents have therape...
|
|
WO/2006/058681A2 |
The invention relates to a method for producing enantiomer-enriched lactones by carbonylating lactones into anhydrides in the presence of a catalyst system, containing: A) at least one carbonylation catalyst A comprised of neutral or ani...
|
|
WO/2006/058121A1 |
The present invention relates to crystalline forms of 3’-tert-Butyl-3’-N-tert-butyloxycarbonyl-4-deacetyl-3’
-dephenyl-3’-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel represented by formula (I); processes for the production thereof...
|
|
WO/2006/037653A1 |
The invention relates to a process for the preparation of 10-deacetyl-Ndebenzoyl-paclitaxel, a synthon useful for the preparation of taxanes with antitumour activity, and intermediates for the preparation thereof. The invention also di...
|
|
WO/2006/035296A1 |
The invention relates to a leucine derivative, N-2[(S)-2-N-formylamino-4-methyl pentanoic acid (S)-1-[[3(S)-hydroxy-5-oxo-4-hexyl methyl]dodecyl ester] amino-4-methyl pentanoic acid (S)-1-[(2S, 3S)-3-hexyl-4-oxo-2-oxetanyl]methyl dodecyl...
|
|
WO/2006/034277A1 |
The present invention provides bicyclic beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer’s disease.
|
|
WO/2006/014356A1 |
Paclitaxel is isolated by a process including normal phase chromatography using a polyamide stationary phase and a mixture containing a dialkyl ketone and a less polar solvent as a mobile phase. Suitable dialkyl ketones include acetone o...
|
|
WO/2006/014345A1 |
Paclitaxel is separated from a mixture containing cephalomannin by column chromatography on silica gel using a solvent mixture containing methyl isobutyl ketone and a less polar solvent as the mobile phase. The less polar solvent can be ...
|
|
WO/2006/005429A1 |
Methods for obtaining paclitaxel from plants containing paclitaxel are disclosed. Plant material is first obtained from plants containing paclitaxel. Paclitaxel is then extracted from the plant material. Subsequently, paclitaxel is separ...
|
|
WO/2006/004898A2 |
A process is provided for the semi-synthesis of taxane derivatives useful in the preparation of docetaxel, in particular, the semi-synthesis of protected taxane derivatives in a one pot reaction of protecting the C-2', C-7 and C-10 and i...
|
|
WO/2006/004708A1 |
A process is provided for the semi-synthesis of taxane intermediates useful in the preparation of paclitaxel and docetaxel, in particular, the semi-synthesis of protected taxane intermediate in a one pot reaction of protecting the C-7, 1...
|
|
WO/2005/118563A1 |
A process is provided for the semi-synthesis of taxane intermediates useful in the preparation of paclitaxel and docetaxel, in particular, the semi-synthesis of protected taxane intermediates.
|
|
WO/2005/113528A1 |
A process for synthesizing a C-7 protected baccatin III compound represented by formula (A), which comprises reacting a 10-deacetylbaccatin III compound represented by formula (B) with a protecting agent and an acylating agent in the pre...
|
|
WO/2005/105767A1 |
A process is provided for the semi-synthesis and isolation of taxane intermediates useful in the preparation of paclitaxel and docetaxel, in particular, the semi-synthesis and isolation of 10-deacetylbaccatin III, the semi-synthesis of a...
|
|
WO/2005/097769A1 |
Novel compounds having naphthalene rings which are expected to be useful as the raw material for resins excellent in thermal resistance, water resistance (resistance to water absorption), and mechanical strengths; and a process for the p...
|
|
WO/2005/095356A1 |
An agent for heat generation or singlet oxygen generation which, unlike anticancer agents of the alkylating agent type such as MMC, destroys cancer cells by the action of heat and/or singlet oxygen and is effective as a new cancer remedy...
|
|
WO/2005/087710A1 |
A compound represented by the formula (1) (wherein the symbols are the same as defined in the description), a salt thereof, and a prodrug thereof. They unexpectedly have excellent GPR40 receptor agonistic activity and are excellent in pr...
|
|
WO/2005/087222A1 |
A taxane having the formula: (I) wherein X3 is furyl, X5 is t-butoxycarbonyl, Bz is benzoyl, and Ac is acetyl.
|
|
WO/2005/082875A2 |
A process is provided for the semi-synthesis of taxane intermediates and aziridine analogues of cephalomannne and baccatin III intermediates, and the conversion of such intermediates and analogues to paclitaxel and docetaxel.
|
|
WO/2005/080366A1 |
The invention relates to substituted $g(b)-lactones (oxetanones) of general formula (I), in which R1, R2 and n have the meanings cited in the description, and to medicaments, which contain these compounds and which have a pancreas lipase...
|
|
WO/2005/080364A1 |
A process by which a novel alicyclic oxetane compound which has an oxetane ring, has excellent light transmission in the near ultraviolet region, and is useful as a cationically polymerizable monomer can be easily obtained. The productio...
|
|
WO/2005/080365A1 |
A process for producing 2,2,3,3-tetrafluorooxetane which comprises reacting tetrafluoroethylene with a formaldehyde source compound in anhydrous hydrogen fluoride, wherein the reaction is conducted in the presence of a polyfluoroalkylcar...
|
|
WO/2005/079398A2 |
A compound having the formula Y - A - Z, wherein: A is a 5, 6, or 7 member ring that is monocyclic or is fused to 1 to 3 additional 4 to 8 member rings; wherein ring A and, independently, the fused additional rings are carbocyclic or het...
|
|
WO/2005/080322A1 |
A novel fluorene characterized by having a fluorene skeleton to which a functional group such as a guanidino group is attached via a carbonyl group, or its salt. This compound has such an advantage as showing a high affinity particularly...
|
|
WO/2005/077984A1 |
A process for producing an organic compound with high yield, which is applicable to a compound of complex structure; and an antibody suitable thereto. It has been found to use an antibody capable of recognizing a target compound of react...
|
|
WO/2005/075445A2 |
The present invention relates to an oxetane compound containing a (meth)acryloyl group represented by formula (1) having a high copolymerizability with compounds containing a (meth) acryloyl group, and to a production method of an oxetan...
|
|
WO/2005/073209A1 |
This invention relates to the preparation process of synthesized taxanoids, including protection the 7-OH with rare earth elements compounds. In this process, the reactions are simple, and the binding is firm and reliable. And in the sub...
|
|
WO/2005/068418A1 |
The invention encompasses novel sulfide and disulfide compounds, compositions comprising sulfide and disulfide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose...
|
|
WO/2005/068449A1 |
The production of lactones ensues by the catalytic carbonylation of oxiranes, during which a catalyst system is used comprised of: a) at least one carbonylation catalyst A composed of neutral or anionic transition metal complexes of meta...
|
|
WO/2005/068420A1 |
The present invention relates to novel urea and thiourea compounds, compositions comprising urea or thiourea compounds, and methods useful for treating and preventing aging, Alzheimer’s Disease, cancer, cardiovascular disease, diabetic...
|
|
WO/2005/068410A1 |
The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders com...
|
|
WO/2005/068412A1 |
The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders c...
|
|
WO/2005/063729A1 |
The present invention provides a novel compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof having a superior GPR40 receptor function modulating action, whic...
|
|
WO/2005/061474A1 |
This invention describes a process for the production of ANHYDROUS active pharmaceutical ingredients (APIs); a process for the preparation of HYDRATED active pharmaceutical ingredients, a process for the preparation of sterile and stable...
|
|
WO/2005/047236A1 |
The present invention relates to sulfoxide and bis-sulfoxide compounds of formula (I), formula (II), or formula (III), compositions comprising sulfoxide and bis-sulfoxide compounds, and methods useful for treating and preventing cardiova...
|
|
WO/2005/044811A2 |
A method is provided for the semi-synthesis of taxane intermediates useful in the preparation of paclitaxel and docetaxel from 9-dihydro-13acetylbaccatin III. The preparation of a suitably protected baccatin III backbone from 9-dihydro...
|
|
WO/2005/041881A2 |
The invention relates to a second-generation-fatty acid conjugate and pharmaceutical compositions thereof. The second-generation-fatty acid conjugate are useful in the treatment of cancer in a human in need thereof.
|
|
WO/2005/040357A2 |
Compounds useful in the fluorescent labeling of biological materials are provided along with methods for their use and preparation.
|
